Brand-name drug
Invokamet price, strengths & recalls
Brand of canagliflozin / metformin (generic)
Pharmacies pay $286.51 for 30 tablets of Invokamet 150 mg / 1000 mg tablet this week, and from $285.55 to $290.63 across its 8 priced strengths and forms. It has 1 recall on record, none ongoing. Its official label last changed on August 25, 2026.
Brand- Fair cash price
- $339.99
- Strengths
- 8
- Makers
- 1
- Updated
- Nov 11
Invokamet price by strength
What pharmacies pay for each strength and form this week (Nov 11, 2026), for 30 tablets. Choose one for its fair price, 52-week chart and makers.
| Strength and form | Per unit | Pharmacies pay |
|---|---|---|
| 50 mg / 1000 mg (24 hr) extended-release tablet Brand | $9.69 | $290.63 / 30 tablets |
| 50 mg / 500 mg (24 hr) extended-release tablet Brand | $9.68 | $290.33 / 30 tablets |
| 150 mg / 1000 mg (24 hr) extended-release tablet Brand | $9.52 | $285.55 / 30 tablets |
| 150 mg / 500 mg (24 hr) extended-release tablet Brand | $9.56 | $286.88 / 30 tablets |
| 50 mg / 1000 mg tablet Brand | $9.54 | $286.29 / 30 tablets |
| 50 mg / 500 mg tablet Brand | $9.56 | $286.94 / 30 tablets |
| 150 mg / 1000 mg tablet Brand | $9.55 | $286.51 / 30 tablets |
| 150 mg / 500 mg tablet Brand | $9.60 | $288.04 / 30 tablets |
The lowest cost per tablet is 150 mg / 1000 mg (24 hr) extended-release tablet at $9.52. Strengths aren't interchangeable - ask your pharmacist or prescriber before changing.
Invokamet vs generic canagliflozin / metformin
There is no generic version of Invokamet on the market yet. Its last listed patent or exclusivity runs to August 26, 2029 - generics often follow, though court cases and settlements can move the date either way.
GenericCanagliflozin / metformin pricesSupply status: shortages & recalls
Recalls
A recall names specific lots. Check the lot number on your package against the recall before you worry - and don't stop a medicine without asking your pharmacist. What to do if your medication is recalled.
What people paid for Invokamet
Bought it recently? Share the price, the pharmacy and how you paid - it's the most useful thing the next person can read.
Official label & what changed
These highlights do not include all the information needed to use INVOKAMET or INVOKAMET XR safely and effectively. See full prescribing information for INVOKAMET or INVOKAMET XR. INVOKAMET® (canagliflozin and metformin hydrochloride) tablets, for oral use INVOKAMET® XR (canagliflozin and metformin hydrochloride) extended-release tablets, for oral use Initial U.S. Approval: 2014
WARNING: LACTIC ACIDOSIS
Post-marketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin-associated lactic acidosis is often subtle, accompanied only by nonspecific symptoms such as malaise, myalgias, respiratory distress, somnolence, and abdominal pain. Metformin-associated lactic acidosis was characterized by elevated blood lactate levels (> 5 mmol/Liter), anion gap acidosis (without evidence of ketonuria or ketonemia), an increased lactate/pyruvate ratio; and metformin plasma levels generally >5 mcg/mL [see Warnings and Precautions (5.1)].
Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs (e.g., carbonic anhydrase inhibitors such as topiramate), age 65 years old or greater, having a radiological study with contrast, surgery and other procedures, hypoxic states (e.g., acute congestive heart failure), excessive alcohol intake, hepatic impairment, and mitochondrial diseases [see Warnings and Precautions (5.1)].
Steps to reduce the risk of and manage metformin-associated lactic acidosis in these high risk groups are provided in the full prescribing information [see Dosage and Administration (2.2, 2.3), Contraindications (4), Warnings and Precautions (5.1), Drug Interactions (7), and Use in Specific Populations (8.6, 8.7)].
If metformin-associated lactic acidosis is suspected, immediately discontinue INVOKAMET or INVOKAMET XR and institute general supportive measures in a hospital setting. Prompt hemodialysis is recommended [see Warnings and Precautions (5.1)].
WARNING: LACTIC ACIDOSIS
See full prescribing information for complete boxed warning.
Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. Symptoms included malaise, myalgias, respiratory distress, somnolence, and abdominal pain. Laboratory abnormalities included elevated blood lactate levels, anion gap acidosis, increased lactate/pyruvate ratio; and metformin plasma levels generally >5 mcg/mL. (5.1)
Risk factors include renal impairment, concomitant use of certain drugs, age >65 years old, radiological studies with contrast, surgery and other procedures, hypoxic states, excessive alcohol intake, hepatic impairment, and mitochondrial diseases. Steps to reduce the risk of and manage metformin-associated lactic acidosis in these high risk groups are provided in the Full Prescribing Information. (5.1)
If lactic acidosis is suspected, discontinue INVOKAMET or INVOKAMET XR and institute general supportive measures in a hospital setting. Prompt hemodialysis is recommended. (5.1)
Recent major changes (as listed on the label)
Boxed Warning | 08/2026 |
Dosage and Administration | |
Recommendations Regarding Missed Dose (2.7) | 08/2026 |
Warnings and Precautions | |
Lactic Acidosis (5.1) | |
Genitourinary Infections, including Urosepsis, Pyelonephritis, Necrotizing Fasciitis of the Perineum
(Fournier's Gangrene), and Genital Mycotic Infections (5.5) | 08/2026 |
We check this label every day. When it changes, the sections that changed appear here, old text beside new.
We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.
Approval, patents & generics
- Application
- NDA205879 · Janssen Pharms
- First approved
- September 20, 2016 (10 years ago)
- Latest approved change
- August 11, 2026
- Approved label
- PDF, Aug 18, 2026
- Generic makers
- None on the market
- Last patent listed
- August 26, 2029
- Exclusivity ends
- June 18, 2028
Patent dates are what the maker lists with FDA. Generic launch dates are often set by court rulings or settlements instead. Upcoming generics.
Invokamet questions
How much does invokamet cost without insurance?
Pharmacies pay about $286.51 for 30 tablets of invokamet 150 mg / 1000 mg tablet ($9.55 per tablet). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $339.99. If you're quoted much more, check your quote and ask for the pharmacy's cash price.
Is there a generic for Invokamet?
Yes: canagliflozin / metformin. Compare canagliflozin / metformin prices.
Is invokamet in shortage?
No shortage is reported for invokamet right now. We check the national shortage list every day.
Has invokamet been recalled?
1 recall on record, none ongoing. Recalls name specific lots - check yours.
When did the invokamet label last change?
The official label was last updated on August 25, 2026 (version 32). See what changed.
Talk about invokamet
No comments yet. Questions, tips, what worked for you - start the conversation.